Moriyama K. Evaluation methods of hepatic steatosis: From conventional techniques to emerging biomarkers. World J Hepatol 2026; 18(1): 112821 [DOI: 10.4254/wjh.v18.i1.112821]
Corresponding Author of This Article
Kengo Moriyama, MD, PhD, Professor, Department of Clinical Health Science, Tokai University School of Medicine, 1838 Ishikawa-machi, Hachioji 1920032, Tokyo, Japan. kengomoriyama@tokai.ac.jp
Research Domain of This Article
Medicine, General & Internal
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Jan 27, 2026 (publication date) through Jan 27, 2026
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Moriyama K. Evaluation methods of hepatic steatosis: From conventional techniques to emerging biomarkers. World J Hepatol 2026; 18(1): 112821 [DOI: 10.4254/wjh.v18.i1.112821]
World J Hepatol. Jan 27, 2026; 18(1): 112821 Published online Jan 27, 2026. doi: 10.4254/wjh.v18.i1.112821
Evaluation methods of hepatic steatosis: From conventional techniques to emerging biomarkers
Kengo Moriyama
Kengo Moriyama, Department of Clinical Health Science, Tokai University School of Medicine, Hachioji 1920032, Tokyo, Japan
Author contributions: Moriyama K conceptualized, designed and wrote the review.
Conflict-of-interest statement: The authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Kengo Moriyama, MD, PhD, Professor, Department of Clinical Health Science, Tokai University School of Medicine, 1838 Ishikawa-machi, Hachioji 1920032, Tokyo, Japan. kengomoriyama@tokai.ac.jp
Received: August 7, 2025 Revised: September 18, 2025 Accepted: December 2, 2025 Published online: January 27, 2026 Processing time: 173 Days and 10.1 Hours
Core Tip
Core Tip: This review provides a comprehensive overview of hepatic steatosis evaluation methods, ranging from conventional ultrasound and liver biopsy to advanced techniques such as magnetic resonance imaging-derived proton density fat fraction, attenuation-based ultrasound, and emerging blood-based and epigenetic biomarkers. By integrating multimodal diagnostic strategies, including artificial intelligence-assisted imaging and methylation profiling, clinicians can improve the diagnosis, risk stratification, and therapeutic monitoring of metabolic dysfunction-associated steatotic liver disease. The review also highlights the evolving role of steatosis quantification as a treatment response marker and future directions in precision hepatology.
